Nocendra

Nocendra is a biotechnology company focused on developing novel small molecule therapeutics targeting the nociceptin system to treat neuropsychiatric and substance use disorders. The company's lead programs center on nociceptin receptor (NOP) agonists and antagonists, aiming to provide safer alternatives to traditional opioids for pain management and effective treatments for opioid use disorder. By leveraging deep expertise in G protein-coupled receptor (GPCR) pharmacology, Nocendra seeks to address significant unmet needs in addiction medicine and mental health. The company is currently in the pre-clinical stage, advancing its proprietary compounds toward regulatory filings.